Showing 1611-1620 of 2050 results for "".
- Aldeyra Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalaphttps://modernod.com/news/aldeyra-therapeutics-achieves-primary-endpoint-in-phase-3-dry-eye-disease-clinical-trial-of-reproxalap/2482391/Aldeyra Therapeutics announced the primary endpoint has been achieved in its phase 3 trial of investigational reproxalap for dry eye disease. In the randomized, double-masked, vehicle-controlled dry eye chamber clinical trial, reproxalap 0.25% was statistic
- FDA Notifies Ocular Therapeutix that SOL-R Trial is Appropriate as a Registrational Study in Wet AMDhttps://modernod.com/news/fda-notifies-ocular-therapeutix-that-sol-r-trial-is-appropriate-as-a-registrational-study-in-wet-amd/2482388/Ocular Therapeutix announced that it has received a written response from the FDA that the phase 3 SOL-R clinical trial is appropriate for use as the company’s second adequate and well controlled study of Axpaxli (axitinib intravitreal implant, also known as OTX-TKI) for the
- AbbVie Launches Refresh Tears PF and Refresh Relieva PF Xtrahttps://modernod.com/news/abbvie-launches-refresh-tears-pf-and-refresh-relieva-pf-xtra/2482369/AbbVie has introduced two new preservative-free (PF) lubricant eye drop products─Refresh Tears PF and Refresh Relieva PF Xtra. According to AbbVie, the new products contain several new features: Multidose Bottle Design: The bottles
- PulseMedica Raises $12 Million to Advance Eye Floater Imaging and Treatment Technologyhttps://modernod.com/news/pulsemedica-raises-12-million-to-advance-eye-floater-imaging-and-treatment-technology/2482360/PulseMedica announced that it has raised an aggregate of $12 million to date in investment as part of their pre-Series A financing round. This investment allowed PulseMedica to generate initial results from their preclinical and clinical studies, and will continue to accelerate the clinical valid
- OcuCell Announces Funding from AltruVision and New Board Appointmentshttps://modernod.com/news/ocucell-announces-funding-from-altruvision-and-leadership-changes/2482354/OcuCell announced it has received funding from AltruVision to enable OcuCell to continue advancing its Endo-Tek and Epi-Tek ocular cell therapy treatments. Financial terms of the funding were not disclosed. Established in 1957, AltruVision recovers over 1,500 eye don
- CDRH Expands TAP Program to Include Ophthalmic Deviceshttps://modernod.com/news/cdrh-expands-tap-program-to-include-ophthalmic-devices/2482344/Jeff Shuren, MD, director of the FDA’s Center for Devices and Radiological Health (CDRH), announced the continued expansion of the Total Product Life Cycle (TPLC) Adv
- Beacon Therapeutics Raises Funds to Advance Development of Its Ophthalmic Gene Therapieshttps://modernod.com/news/beacon-therapeutics-raises-funds-to-advance-development-of-its-ophthalmic-gene-therapies/2482341/Beacon Therapeutics announced it has raised $170 million in Series B funding, which will be used to support the continued clinical development of Beacon’s lead asset, AGTC-501, for X-linked retinitis pigmentosa (XLRP; laruparetigene zovaparvovec) and generate phase 1/2 clinical trial d
- Beacon Therapeutics Treats First Patient in VISTA Trial of AGTC-501 for XLRPhttps://modernod.com/news/beacon-therapeutics-treats-first-patient-in-vista-registrational-trial-for-agtc-501/2482319/Beacon Therapeutics announced the treatment of the first patient in its registrational VISTA clinical trial with its lead asset, AGTC-501 (laruparetigene zovaparvovec). VISTA is a global randomized, controlled, masked, multicenter pivotal study evaluating the efficacy, safety, and
- Nidek Receives CE Mark Approval for Preloaded IOL Injection Systemhttps://modernod.com/news/nidek-receives-ce-mark-approval-for-preloaded-iol-injection-system/2482315/Nidek has received CE Mark for the NP-1/NP-1C Preloaded IOL Injection System, a fully preloaded injection system with an aspheric hydrophobic soft acrylic lens designed for smoother, safer, and secure IOL implantation. The NP-1/NP-1C injector is developed for smooth, controlle
- Nominations Now Being Accepted for Neuro-Optometric Rehabilitation Association Awardshttps://modernod.com/news/nominations-now-being-accepted-for-neuro-optometric-rehabilitation-association-awards/2482308/Nominations are now being accepted by the Neuro-Optometric Rehabilitation Association, International (NORA) for the following awards, which acknowledge individuals and organizations for important contributions to the area of neuro-optometric rehabilitation. The Advancement of Neur